RegenLab USA, Inc. (RGNA)

RegenLab USA Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Revenue Revenue Growth	54.26	49.17	48.38
Revenue Growth	-	1.63%	-
Gross Profit Gross Profit Growth	37.49	34.24	34.47
Operating Income Operating Income Growth	3.54	0.68	3.48
Net Income Net Income Growth	-1.14	-1.24	2.31

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	4.83	1.85	0.96
Total Debt Total Debt Growth	40.04	41.61	33.13
Net Cash (Debt) Net Cash Growth	-35.22	-39.76	-32.18
Net Cash Growth	-	-	-

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	4.09	-0.54	4.43
Capital Expenditures CapEx Growth	-1.29	-1.57	-3.16
Free Cash Flow Free Cash Flow Growth	2.8	-2.11	1.28
Free Cash Flow Growth	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Gross Margin	69.08%	69.63%	71.24%
Operating Margin	6.53%	1.37%	7.19%
Pretax Margin	-2.33%	-1.82%	5.80%
Profit Margin	-2.10%	-2.52%	4.78%
FCF Margin	5.16%	-4.30%	2.64%

Data Source: SEC filings Last updated: Dec 31, 2025

The financial data was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error